AZNAstraZenecaRunning, no new patients
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Gastric Cancer · Gastroesophageal Junction Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 594 (final count)
- Started
- Mar 4, 2024
- Main results expected
- May 31, 2026
- Fully finished
- Oct 14, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) in all randomized participants
Measured over: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).
Overall Survival (OS) for 3L+ participants
Measured over: From date of first dose/randomisation until the date of death due to any cause (approximately 3 years).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06346392 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC